1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Rim and flame signs in intramedullary spinal cord metastases (per-patient basis)
Rim Sign Only Flame Sign Only Both Signs Neither Sign At Least One Sign
All ISCMs (n = 45) 9 (20%) 6 (13%) 12 (27%) 18 (40%) 27 (60%)
Lung carcinoma (n = 22) 6 (27%) 3 (14%) 8 (36%) 5 (23%) 17 (77%)
Breast carcinoma (n = 6) 0 0 1 (17%) 5 (83%) 1 (17%)
Melanoma (n = 5) 0 1 (20%) 1 (20%) 3 (60%) 2 (40%)
CNS origin (n = 4) 0 0 0 4 (100%) 0
Renal cell carcinoma (n = 2) 0 1 (50%) 1 (50%) 0 2 (100%)
Other (n = 6) 3 (50%) 1 (17%) 1 (17%) 1 (17%) 5 (83%)
ISCM identified prior to systemic metastatic disease diagnosis (n = 10) 3 (30%) 2 (20%) 4 (40%) 1 (10%) 9 (90%)
Radiation therapy for primary malignancy included relevant spinal cord (n = 5) 0 1 (20%) 3 (60%) 1 (20%) 4 (80%)
Ongoing systemic steroid therapy at time of MRI (n = 12) 2 (17%) 2 (17%) 3 (25%) 5 (42%) 7 (58%)